A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Nitric oxide (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Novan Inc
- 05 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
- 05 Dec 2017 According to a Novan media release, first patient has been dosed in the trial. Top line results are targeted for the third quarter of 2018.
- 05 Dec 2017 Status changed from planning to recruiting, according to a Novan media release.